DURECT Corporation – NASDAQ:DRRX
DURECT stock price today
DURECT stock price monthly change
DURECT stock price quarterly change
DURECT stock price yearly change
DURECT key metrics
Market Cap | 29.20M |
Enterprise value | 78.66M |
P/E | -2.84 |
EV/Sales | 4.07 |
EV/EBITDA | -2.39 |
Price/Sales | 5.12 |
Price/Book | 3.95 |
PEG ratio | -0.90 |
EPS | -0.86 |
Revenue | 8.32M |
EBITDA | -30.48M |
Income | -23.28M |
Revenue Q/Q | -11.05% |
Revenue Y/Y | -57.15% |
Profit margin | -183.23% |
Oper. margin | -181.93% |
Gross margin | 91.76% |
EBIT margin | -181.93% |
EBITDA margin | -366.39% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeDURECT stock price history
DURECT stock forecast
DURECT financial statements
| Jun 2023 | 2.08M | -11.18M | -537.29% |
|---|---|---|---|
| Sep 2023 | 1.74M | -3.01M | -172.88% |
| Dec 2023 | 2.66M | -1.44M | -53.99% |
| Mar 2024 | 1.82M | -7.64M | -418.34% |
| 2025 | 18.03M | -33.08M | -183.43% |
|---|---|---|---|
| 2026 | 23.65M | -37.57M | -158.85% |
| 2027 | 59.35M | -9.28M | -15.64% |
| 2028 | 145.12M | 46.67M | 32.16% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 48657000 | 43.15M | 88.7% |
|---|---|---|---|
| Sep 2023 | 54728000 | 40.32M | 73.68% |
| Dec 2023 | 45189000 | 30.40M | 67.29% |
| Mar 2024 | 36221000 | 27.92M | 77.09% |
| Jun 2023 | -9.34M | 1.84M | -34K |
|---|---|---|---|
| Sep 2023 | -7.48M | 2.95M | 11.75M |
| Dec 2023 | -8.32M | -1.03M | -1.22M |
| Mar 2024 | -6.76M | -887K | -1.49M |
DURECT alternative data
| Aug 2023 | 75 |
|---|---|
| Sep 2023 | 72 |
| Oct 2023 | 72 |
| Nov 2023 | 72 |
| Dec 2023 | 72 |
| Jan 2024 | 72 |
| Feb 2024 | 72 |
| Mar 2024 | 72 |
| Apr 2024 | 72 |
| May 2024 | 58 |
| Jun 2024 | 58 |
| Jul 2024 | 48 |
DURECT other data
| Period | Buy | Sel |
|---|---|---|
| Dec 2021 | 20000 | 0 |
| Mar 2022 | 200000 | 0 |
| May 2022 | 225000 | 0 |
| Aug 2022 | 291131 | 0 |
| Patent |
|---|
Application Filling date: 14 Feb 2022 Issue date: 8 Sep 2022 |
Application Filling date: 13 May 2022 Issue date: 1 Sep 2022 |
Grant Filling date: 19 Oct 2021 Issue date: 2 Aug 2022 |
Application COMPOSITIONS COMPRISING OXYGENATED CHOLESTEROL SULFATE AND AT LEAST ONE OF POLYALKYLENE GLYCOL, CARBOXYMETHYL CELLULOSE AND POLYOXYLGLYCERIDE Filling date: 15 Nov 2021 Issue date: 9 Jun 2022 |
Application Filling date: 19 Oct 2021 Issue date: 5 May 2022 |
Grant Utility: Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material Filling date: 1 Jun 2020 Issue date: 29 Mar 2022 |
Application Filling date: 30 Jun 2021 Issue date: 27 Jan 2022 |
Grant Utility: Short duration depot formulations Filling date: 26 Sep 2019 Issue date: 23 Nov 2021 |
Application Filling date: 9 Apr 2021 Issue date: 28 Oct 2021 |
Application Filling date: 5 Apr 2021 Issue date: 21 Oct 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 13 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 13 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. James E. Brown D.V.M. (1957) Co-Founder, Chief Executive Officer, Pres & Director | $775,880 |
| Mr. Michael H. Arenberg (1970) Chief Financial Officer & Sec. | $452,940 |
| Dr. Norman L. Sussman (1953) Chief Medical Officer | $419,680 |
| Ms. Judy R. Joice (1957) Senior Vice President of Operations & Corporation Quality Assurance | $406,510 |
-
What's the price of DURECT stock today?
One share of DURECT stock can currently be purchased for approximately $1.88.
-
When is DURECT's next earnings date?
Unfortunately, DURECT's (DRRX) next earnings date is currently unknown.
-
Does DURECT pay dividends?
No, DURECT does not pay dividends.
-
How much money does DURECT make?
DURECT has a market capitalization of 29.20M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 55.67% to 8.55M US dollars.
-
What is DURECT's stock symbol?
DURECT Corporation is traded on the NASDAQ under the ticker symbol "DRRX".
-
What is DURECT's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of DURECT?
Shares of DURECT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are DURECT's key executives?
DURECT's management team includes the following people:
- Dr. James E. Brown D.V.M. Co-Founder, Chief Executive Officer, Pres & Director(age: 68, pay: $775,880)
- Mr. Michael H. Arenberg Chief Financial Officer & Sec.(age: 55, pay: $452,940)
- Dr. Norman L. Sussman Chief Medical Officer(age: 72, pay: $419,680)
- Ms. Judy R. Joice Senior Vice President of Operations & Corporation Quality Assurance(age: 68, pay: $406,510)
-
Is DURECT founder-led company?
Yes, DURECT is a company led by its founder Dr. James E. Brown D.V.M..
-
How many employees does DURECT have?
As Jul 2024, DURECT employs 48 workers, which is 17% less then previous month and 33% less then previous quarter.
-
When DURECT went public?
DURECT Corporation is publicly traded company for more then 24 years since IPO on 28 Sep 2000.
-
What is DURECT's official website?
The official website for DURECT is durect.com.
-
Where are DURECT's headquarters?
DURECT is headquartered at 10260 Bubb Road, Cupertino, CA.
-
How can i contact DURECT?
DURECT's mailing address is 10260 Bubb Road, Cupertino, CA and company can be reached via phone at +40 87771417.
DURECT company profile:
DURECT Corporation
durect.comNASDAQ
48
Drug Manufacturers - Specialty & Generic
Healthcare
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Cupertino, CA 95014-4166
CIK: 0001082038
ISIN: US2666055007
CUSIP: 266605104
